Andrew Schiermeier
Chief Executive Officer at AvenCell Therapeutics, Inc.
Profile
Andrew D. Schiermeier is on the board of Kynan Pharmaceuticals and Chief Operating Officer of Intellia Therapeutics, Inc. In his past career he occupied the position of Chief Operating Officer at Aura Biosciences, Inc. and Senior CP & Head-Oncology Business at Merck KGaA. He received an MBA from College des Ingenieurs, a doctorate from Harvard University and a graduate degree from Stanford University.
Andrew Schiermeier active positions
| Companies | Position | Start |
|---|---|---|
| Kynan Pharmaceuticals | Director/Board Member | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Chief Executive Officer | 2021-07-31 |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Director/Board Member | - |
Former positions of Andrew Schiermeier
| Companies | Position | End |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Operating Officer | 2021-06-20 |
| MERCK KGAA | Corporate Officer/Principal | 2015-12-31 |
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 2013-04-30 |
Training of Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
- Stock Market
- Insiders
- Andrew Schiermeier
